FDA allows StemCells to expand trial to U.S.

October 7, 2013

StemCells Inc. said it received authorization to start a clinical trial of its purified stem cell therapy as a treatment for chronic spinal cord injury. The company said the Food and Drug Administration approved its investigational new drug application, meaning StemCells can start testing the treatment on humans in the U.S. The trial started about a year ago and it currently includes a total of seven patients. Treatment is being administered in Switzerland and Canada. (Drug, Discovery, & Development)